Matching articles for "LMWH"
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • November 1, 2009; (Issue 87)
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases...
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Antiplatelet and Anticoagulant Drugs
The Medical Letter on Drugs and Therapeutics • May 1, 2008; (Issue 69)
Arterial and venous thrombosis are major causes of morbidity and mortality. Arterial thrombi consist of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice...
Arterial and venous thrombosis are major causes of morbidity and mortality. Arterial thrombi consist of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Drugs for Percutaneous Coronary Interventions
The Medical Letter on Drugs and Therapeutics • December 6, 2004; (Issue 1197)
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • February 19, 2001; (Issue 1098)
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.